Professor Frédéric Ris studied medicine at the University of Geneva, where he graduated in 1999.
After 2 years of research within the Cell Therapy Laboratory of the University Hospitals of Geneva, he trained in general surgery in Switzerland, between Lachen and Geneva, as well as in Belgium. He became FMH specialist in surgery in 2008. Professor Ris then specialized in colorectal surgery at the University Hospitals of Oxford (2010-2011) and obtained in European certification as specialist in coloproctologic surgery in 2011 (ESBQ). Professor Ris was appointed Consultant surgeon at the University Hospitals of Geneva in 2012. He became FMH specialist in digestive surgery in 2013. He developed the surgical activities of the Division of Digestive surgery in colorectal surgery, proctology and perineal floor. In parallel, Professor Ris obtained the title of Doctor in medicine (MD) for his research on MRI imaging of pancreatic islets, and the title of Privat Docent (PD) for his research on virtual reality and fluorescence in surgery. Professor Ris was appointed Professor at the Faculty of Medicine of the University of Geneva in November 2018 . His research has received several awards, including the Swiss College of Surgeons award and the Marc-Claude Marti award. He has published over 198 articles and book chapters and his H index is at 28.
His main areas are the following :
- colorectal and oncological surgery (notably accelerated rehabilitation after surgery)
- pelvic floor and proctology (with innovative approaches to repair the puborectal muscle)
- new technologies (with a specific interest in augmented reality and indocyanine green for visualization of bowel vascularization and lymph nodes)
- teaching of surgery.
Professor Ris is an expert in minimally invasive colorectal surgery (IBD, oncology and MHS rectal surgery) and pelvic floor disorders. He is also responsible for the management of abdominal peritoneal carcinoma (intra-abdominal hyperthermic chemotherapy and PIPAC) and works regularly with the team of gynecology on ovarian carcinoma. He is one of the founding members of the Swiss group for the management of this disease (Swiss peritoneal cancer group).